1
|
De Robertis M, Pasquet L, Loiacono L, Bellard E, Messina L, Vaccaro S, Di Pasquale R, Fazio VM, Rols MP, Teissie J, Golzio M, Signori E. In Vivo Evaluation of a New Recombinant Hyaluronidase to Improve Gene Electro-Transfer Protocols for DNA-Based Drug Delivery against Cancer. Cancers (Basel) 2018; 10:cancers10110405. [PMID: 30373297 PMCID: PMC6265783 DOI: 10.3390/cancers10110405] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2018] [Revised: 10/08/2018] [Accepted: 10/26/2018] [Indexed: 12/20/2022] Open
Abstract
Cancer vaccines based on plasmid DNA represent a good therapeutic perspective, despite their low potency. Animal-derived hyaluronidases (Hyals) are employed in oncological clinical practice. Hyal has been also demonstrated to be a good enhancer of intramuscular Gene Electro-Transfer (GET) efficiency in anti-cancer preclinical protocols, with increased transfected cells and higher expression of the encoded genes. Nevertheless, the use of animal-derived Hyals results limited respect to their potentialities, since such preparations could be affected by low purity, variable potency and uncertain safety. To improve the delivery of intramuscular GET-based protocols in mouse, we investigated a new recombinant Hyal, the rHyal-sk, to assess in vivo safety and activity of this treatment at cellular and biochemical levels. We evaluated the cellular events and the inflammation chemical mediators involved at different time points after rHyal-sk administration plus GET. Our results demonstrated the in vivo safety and efficacy of rHyal-sk when injected once intramuscularly in association with GET, with no toxicity, good plasmid in-take ability, useful inflammatory response activation, and low immunogenicity. Following these findings, we would recommend the use of the new rHyal-sk for the delivery of DNA-based vaccines and immunotherapy, as well as into clinical practice, for tumor disease treatments.
Collapse
Affiliation(s)
- Mariangela De Robertis
- Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari "A. Moro", via Orabona 4, 70126 Bari, Italy.
- Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, via Alvaro del Portillo 21, 00128 Rome, Italy.
- CNR-Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy.
| | - Lise Pasquet
- Vaccine Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, BP64182, 205 Route de Narbonne, 31077 Toulouse, France.
| | - Luisa Loiacono
- Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, via Alvaro del Portillo 21, 00128 Rome, Italy.
- New Drug Modalities, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge CB4 0WG, UK.
| | - Elisabeth Bellard
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, BP64182, 205 Route de Narbonne, 31077 Toulouse, France.
| | - Luciano Messina
- Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Contrada Pizzuta snc, 96017 Noto, Siracusa, Italy.
| | - Susanna Vaccaro
- Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Contrada Pizzuta snc, 96017 Noto, Siracusa, Italy.
| | - Roberta Di Pasquale
- Fidia Farmaceutici S.p.A., Local Unit Fidia Research Sud, Contrada Pizzuta snc, 96017 Noto, Siracusa, Italy.
| | - Vito Michele Fazio
- Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, via Alvaro del Portillo 21, 00128 Rome, Italy.
- Fondazione IRCCS Casa Sollievo della Sofferenza, Laboratorio di Oncologia, viale dei Cappuccini, 71013 San Giovanni Rotondo (FG), Italy.
| | - Marie-Pierre Rols
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, BP64182, 205 Route de Narbonne, 31077 Toulouse, France.
| | - Justin Teissie
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, BP64182, 205 Route de Narbonne, 31077 Toulouse, France.
| | - Muriel Golzio
- Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, BP64182, 205 Route de Narbonne, 31077 Toulouse, France.
| | - Emanuela Signori
- Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, via Alvaro del Portillo 21, 00128 Rome, Italy.
- CNR-Institute of Translational Pharmacology, Via Fosso del Cavaliere 100, 00133 Rome, Italy.
| |
Collapse
|